450 related articles for article (PubMed ID: 25391420)
1. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe.
Tsiftsoglou AS; Trouvin JH; Calvo G; Ruiz S
BioDrugs; 2014 Dec; 28(6):479-86. PubMed ID: 25391420
[TBL] [Abstract][Full Text] [Related]
2. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
3. Comparability and biosimilarity: considerations for the healthcare provider.
Lee JF; Litten JB; Grampp G
Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
[TBL] [Abstract][Full Text] [Related]
4. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
Schiestl M; Zabransky M; Sörgel F
Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: controversies as illustrated by rhGH.
Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
[TBL] [Abstract][Full Text] [Related]
6. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
8. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
9. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
10. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
11. Molecular "Sameness" Is the Key Guiding Principle for Extrapolation to Multiple Indications.
McCamish M; Woollett GR
Clin Pharmacol Ther; 2017 May; 101(5):603-605. PubMed ID: 28074488
[TBL] [Abstract][Full Text] [Related]
12. From bioequivalence to biosimilars: How much do regulators dare?
Weise M
Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: in support of extrapolation of indications.
Ebbers HC
J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
van Aerts LA; De Smet K; Reichmann G; van der Laan JW; Schneider CK
MAbs; 2014; 6(5):1155-62. PubMed ID: 25517301
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the EU Biosimilar Framework: Past and Future.
Wolff-Holz E; Tiitso K; Vleminckx C; Weise M
BioDrugs; 2019 Dec; 33(6):621-634. PubMed ID: 31541400
[TBL] [Abstract][Full Text] [Related]
17. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
18. [Opportunities and challenges of extrapolation for biosimilars].
Weise M; Wolff-Holz E
Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
[TBL] [Abstract][Full Text] [Related]
19. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
20. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab.
Ebbers HC; van Meer PJ; Moors EH; Mantel-Teeuwisse AK; Leufkens HG; Schellekens H
Drug Discov Today; 2013 Sep; 18(17-18):872-9. PubMed ID: 23688584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]